GernertJAKleinMSchöberlF, et al. Severe course of tick-borne encephalitis (TBE) in a patient with relapsing multiple sclerosis (MS) treated with ocrelizumab. Mult Scler J2026: 652–657.
2.
BenoitPBrazerNde Lorenzi-TognonM, et al. Seven-year performance of a clinical metagenomic next-generation sequencing test for diagnosis of central nervous system infections. Nat Med2024; 30(12): 3522–3533.
3.
Redelman-SidiGMichielinOCerveraC, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: An infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin Microbiol Infect2018; 24(Suppl. 2): S95–S107.
4.
WinkelmannAMetzeCFrimmelS, et al. Tick-borne encephalitis vaccination in multiple sclerosis: A prospective, multicenter study. Neurol Neuroimmunol Neuroinflamm2020; 7(2): e664.
5.
Otero-RomeroSLebrun-FrénayCReyesS, et al. ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs. Mult Scler2023; 29(8): 904–925.
